# Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites

> **NCT01852409** · PHASE1 · UNKNOWN · sponsor: **Peking University** · enrollment: 18 (estimated)

## Conditions studied

- Refractory Malignant Ascites

## Interventions

- **DRUG:** bevacizumab

## Key facts

- **NCT ID:** NCT01852409
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2015-06
- **Final completion:** 2015-06
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2013-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01852409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01852409, "Phase I Trial of Intraperitoneal Bevacizumab in Refractory Malignant Ascites". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01852409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*